Arcus Biosciences (RCUS) Stock Price, News & Analysis

Company Overview

Arcus Biosciences, Inc. is a biopharmaceutical company focused on discovering and developing medicines for the treatment of cancer. The company uses a proprietary research platform to develop small-molecule and antibody-based therapies designed to target biological mechanisms involved in tumor growth and immune-system regulation.

Arcus’ oncology pipeline has included investigational therapies such as zimberelimab, an anti-PD-1 antibody; domvanalimab, an anti-TIGIT antibody; quemliclustat, a CD73 inhibitor; and etrumadenant, an adenosine receptor antagonist. These candidates are being evaluated in combination regimens and across multiple cancer types, including lung and gastrointestinal cancers. The company does not have a broad portfolio of marketed products and remains primarily focused on clinical-stage development.

Founded in 2015 and headquartered in Hayward, California, Arcus conducts research and clinical development activities through collaborations and studies involving institutions and patients in the United States and other international markets. The company has maintained a strategic partnership with Gilead Sciences to advance and commercialize certain oncology programs. Arcus was co-founded and is led by Terry Rosen, Ph.D., who serves as chief executive officer.

Key Stats

• Today's Range: $24.09 to $25.58
• 50-Day Range: $24.04 to $31.42
• 52-Week Range: $13.21 to $31.74
• Volume: 1.04 million shs
• Average Volume: 1.72 million shs
• Market Capitalization: $3.11 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $38.30
• Consensus Rating: Moderate Buy

Arcus Biosciences Stock Analysis - MarketRank™

Arcus Biosciences scored higher than 58% of companies evaluated by MarketBeat, and ranked 372nd out of 888 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Arcus Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 10 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Arcus Biosciences has a consensus price target of $38.30, representing about 56.8% upside from its current price of $24.43.

Amount of Analyst Coverage

Arcus Biosciences has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Arcus Biosciences are expected to grow in the coming year, from ($3.53) to ($3.24) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Arcus Biosciences is -6.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Arcus Biosciences is -6.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Arcus Biosciences has a P/B Ratio of 4.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.74% of the float of Arcus Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Arcus Biosciences has a short interest ratio ("days to cover") of 7.81.

Change versus previous month

Short interest in Arcus Biosciences has recently increased by 5.63%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Arcus Biosciences does not currently pay a dividend.

Dividend Growth

Arcus Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.35

News Sentiment

Arcus Biosciences has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.49 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Arcus Biosciences this week, compared to 5 articles on an average week.

Search Interest

9 people have searched for RCUS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Arcus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,116,613.00 in company stock.

Percentage Held by Insiders

7.60% of the stock of Arcus Biosciences is held by insiders.

Percentage Held by Institutions

92.89% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/05/2026
• Today: 10/02/2026
• Investor update: 10/20/2026
• Next Earnings (Estimated): 10/27/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NYSE:RCUS
• CIK: 1724521
• Web: www.arcusbio.com
• Phone: (510) 694-6200
• Fax: N/A
• Employees: 601
• Year Founded: 2015

Price Target and Rating

• Average Price Target for Arcus Biosciences: $38.30
• High Price Target: $47.00
• Low Price Target: $23.00
• Potential Upside/Downside: +56.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 14 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$353 million
• Net Margins: -393.16%
• Pretax Margin: -393.16%
• Return on Equity: -89.54%
• Return on Assets: -45.61%

Debt

• Debt-to-Equity Ratio: 0.22
• Current Ratio: 3.82
• Quick Ratio: 3.82

Sales & Book Value

• Annual Sales: $247 million
• Price / Sales: 12.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.84 per share
• Price / Book: 4.18

Miscellaneous

• Outstanding Shares: 127,330,000
• Free Float: 117,656,000
• Market Cap: $3.11 billion
• Optionable: Optionable
• Beta: 0.94